Drug profile · INN
lebrikizumab-lbkz
EBGLYSS
lebrikizumab-lbkz (EBGLYSS) is a interleukin-13 inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — lebrikizumab-lbkz
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
lebrikizumab-lbkz (EBGLYSS) is a interleukin-13 inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Interleukin-13 inhibitor
Primary target: Interleukin-13
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is lebrikizumab-lbkz?
lebrikizumab-lbkz (EBGLYSS) is a interleukin-13 inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for lebrikizumab-lbkz?
EBGLYSS is a marketed brand name for lebrikizumab-lbkz. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of lebrikizumab-lbkz?
lebrikizumab-lbkz has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.